{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:16:48Z","timestamp":1793744208291,"version":"4.6.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Malignant pleural mesothelioma (MPM) is an aggressive tumor with a poor prognosis. As the available therapeutic options show a lack of efficacy, novel therapeutic strategies are urgently needed. Given its T-cell infiltration, we hypothesized that MPM is a suitable target for therapeutic cancer vaccination. To date, research on mesothelioma has focused on the identification of molecular signatures to better classify and characterize the disease, and little is known about therapeutic targets that engage cytotoxic (CD8+) T cells. In this study we investigate the immunopeptidomic antigen-presented landscape of MPM in both murine (AB12 cell line) and human cell lines (H28, MSTO-211H, H2452, and JL1), as well as in patients\u2019 primary tumors. Applying state-of-the-art immuno-affinity purification methodologies, we identify MHC I-restricted peptides presented on the surface of malignant cells. We characterize in vitro the immunogenicity profile of the eluted peptides using T cells from human healthy donors and cancer patients. Furthermore, we use the most promising peptides to formulate an oncolytic virus-based precision immunotherapy (PeptiCRAd) and test its efficacy in a mouse model of mesothelioma in female mice. Overall, we demonstrate that the use of immunopeptidomic analysis in combination with oncolytic immunotherapy represents a feasible and effective strategy to tackle untreatable tumors.<\/jats:p>","DOI":"10.1038\/s41467-023-42668-7","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T08:02:55Z","timestamp":1698998575000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors"],"prefix":"10.1038","volume":"14","author":[{"given":"Jacopo","family":"Chiaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Antignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4012-4310","authenticated-orcid":false,"given":"Sara","family":"Feola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6094-9838","authenticated-orcid":false,"given":"Michaela","family":"Feodoroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"Cojoc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-3018","authenticated-orcid":false,"given":"Manlio","family":"Fusciello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4678-7382","authenticated-orcid":false,"given":"Firas","family":"Hamdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6523-3049","authenticated-orcid":false,"given":"Daniele","family":"Ciampi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8149-3550","authenticated-orcid":false,"given":"Ilkka","family":"Ilonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jari","family":"R\u00e4s\u00e4nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0877-9640","authenticated-orcid":false,"given":"Mikko","family":"M\u00e4yr\u00e4np\u00e4\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6681-4734","authenticated-orcid":false,"given":"Jukka","family":"Partanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9258-9163","authenticated-orcid":false,"given":"Satu","family":"Koskela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarno","family":"Honkanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jussi","family":"Halonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1887-6361","authenticated-orcid":false,"given":"Lukasz","family":"Kuryk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6464-509X","authenticated-orcid":false,"given":"Maria","family":"Rescigno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikaela","family":"Gr\u00f6nholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3890-6476","authenticated-orcid":false,"given":"Rui M.","family":"Branca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8100-9562","authenticated-orcid":false,"given":"Janne","family":"Lehti\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4901-3796","authenticated-orcid":false,"given":"Vincenzo","family":"Cerullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,3]]},"reference":[{"key":"42668_CR1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3389\/fonc.2019.00078","volume":"9","author":"J-G Zhou","year":"2019","unstructured":"Zhou, J.-G. et al. Development and validation of a prognostic signature for malignant pleural mesothelioma. Front. Oncol. 9, 78 (2019).","journal-title":"Front. Oncol."},{"key":"42668_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1080\/0284186X.2018.1532599","volume":"58","author":"S Laaksonen","year":"2019","unstructured":"Laaksonen, S. et al. Malignant pleural mesothelioma in Finland: regional and gender variation. Acta Oncol. 58, 38\u201344 (2019).","journal-title":"Acta Oncol."},{"key":"42668_CR3","doi-asserted-by":"publisher","first-page":"916839","DOI":"10.3389\/fonc.2022.916839","volume":"12","author":"L Kuryk","year":"2022","unstructured":"Kuryk, L. et al. Novel insights into mesothelioma therapy: emerging avenues and future prospects. Front. Oncol. 12, 916839 (2022).","journal-title":"Front. Oncol."},{"key":"42668_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41588-020-00752-4","volume":"53","author":"C Valero","year":"2021","unstructured":"Valero, C. et al. The association between tumor mutational burden and prognosis is dependent on treatment context. Nat. Genet. 53, 11\u201315 (2021).","journal-title":"Nat. Genet."},{"key":"42668_CR5","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.3389\/fonc.2019.01366","volume":"9","author":"GJ Chu","year":"2019","unstructured":"Chu, G. J., van Zandwijk, N. & Rasko, J. E. J. The immune microenvironment in mesothelioma: mechanisms of resistance to immunotherapy. Front. Oncol. 9, 1366 (2019).","journal-title":"Front. Oncol."},{"key":"42668_CR6","doi-asserted-by":"publisher","first-page":"e1105429","DOI":"10.1080\/2162402X.2015.1105429","volume":"5","author":"C Capasso","year":"2016","unstructured":"Capasso, C. et al. Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma. Oncoimmunology 5, e1105429 (2016).","journal-title":"Oncoimmunology"},{"key":"42668_CR7","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1158\/2326-6066.CIR-20-0814","volume":"9","author":"J Chiaro","year":"2021","unstructured":"Chiaro, J. et al. Viral molecular mimicry influences the antitumor immune response in murine and human melanoma. Cancer Immunol. Res. 9, 981\u2013993 (2021).","journal-title":"Cancer Immunol. Res."},{"key":"42668_CR8","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.3390\/cancers13143408","volume":"13","author":"K Peltonen","year":"2021","unstructured":"Peltonen, K. et al. Therapeutic cancer vaccination with immunopeptidomics-discovered antigens confers protective antitumor efficacy. Cancers 13, 3408 (2021).","journal-title":"Cancers"},{"key":"42668_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1158\/0008-5472.CAN-19-2062","volume":"80","author":"S T\u00e4htinen","year":"2020","unstructured":"T\u00e4htinen, S. et al. Exploiting preexisting immunity to enhance oncolytic cancer immunotherapy. Cancer Res. 80, 12 (2020).","journal-title":"Cancer Res."},{"key":"42668_CR10","doi-asserted-by":"publisher","first-page":"e71156","DOI":"10.7554\/eLife.71156","volume":"11","author":"S Feola","year":"2022","unstructured":"Feola, S. et al. A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines. Elife 11, e71156 (2022).","journal-title":"Elife"},{"key":"42668_CR11","doi-asserted-by":"publisher","first-page":"826164","DOI":"10.3389\/fimmu.2022.826164","volume":"13","author":"S Feola","year":"2022","unstructured":"Feola, S. et al. Peptides-coated oncolytic vaccines for cancer personalized medicine. Front. Immunol. 13, 826164 (2022).","journal-title":"Front. Immunol."},{"key":"42668_CR12","doi-asserted-by":"publisher","first-page":"615234","DOI":"10.3389\/fonc.2021.615234","volume":"11","author":"W Duan","year":"2021","unstructured":"Duan, W. et al. Combined analysis of RNA sequence and microarray data reveals a competing endogenous RNA network as novel prognostic markers in malignant pleural mesothelioma. Front. Oncol. 11, 615234 (2021).","journal-title":"Front. Oncol."},{"key":"42668_CR13","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.3390\/ijms22052738","volume":"22","author":"F Morani","year":"2021","unstructured":"Morani, F. et al. Identification of overexpressed genes in malignant pleural mesothelioma. Int. J. Mol. Sci. 22, 2738 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"42668_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-021-00264-1","volume":"9","author":"L Castelletti","year":"2021","unstructured":"Castelletti, L., Yeo, D., van Zandwijk, N. & Rasko, J. E. J. Anti-mesothelin CAR T cell therapy for malignant mesothelioma. Biomark. Res. 9, 11 (2021).","journal-title":"Biomark. Res."},{"key":"42668_CR15","doi-asserted-by":"publisher","first-page":"103107","DOI":"10.1016\/j.isci.2021.103107","volume":"24","author":"X Yi","year":"2021","unstructured":"Yi, X. et al. caAtlas: an immunopeptidome atlas of human cancer. iScience 24, 103107 (2021).","journal-title":"iScience"},{"key":"42668_CR16","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.jtho.2021.10.022","volume":"17","author":"F Kosari","year":"2022","unstructured":"Kosari, F. et al. Tumor junction burden and antigen presentation as predictors of survival in mesothelioma treated with immune checkpoint inhibitors. J. Thorac. Oncol. 17, 446\u2013454 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"42668_CR17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.cels.2020.06.010","volume":"11","author":"O\u2019Donnell","year":"2020","unstructured":"O\u2019Donnell et al. MHCflurry 2.0: improved pan-allele prediction of MHC class I-presented peptides by incorporating antigen processing. Cell Syst. 11, 42\u201348.e47 (2020).","journal-title":"Cell Syst."},{"key":"42668_CR18","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.cell.2019.12.023","volume":"180","author":"DP Nusinow","year":"2020","unstructured":"Nusinow, D. P. et al. Quantitative proteomics of the cancer cell line encyclopedia. Cell 180, 387\u2013402.e316 (2020).","journal-title":"Cell"},{"key":"42668_CR19","doi-asserted-by":"publisher","first-page":"D339","DOI":"10.1093\/nar\/gky1006","volume":"47","author":"R Vita","year":"2019","unstructured":"Vita, R. et al. The immune epitope database (IEDB): 2018 update. Nucleic Acids Res. 47, D339\u2013D343 (2019).","journal-title":"Nucleic Acids Res."},{"key":"42668_CR20","doi-asserted-by":"publisher","first-page":"S369","DOI":"10.21037\/jtd.2017.10.158","volume":"10","author":"E Barone","year":"2017","unstructured":"Barone, E., Gemignani, F. & Landi, S. Overexpressed genes in malignant pleural mesothelioma: implications in clinical management. J. Thorac. Dis. 10, S369\u2013S382 (2017).","journal-title":"J. Thorac. Dis."},{"key":"42668_CR21","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/ijc.2910520609","volume":"52","author":"MR Davis","year":"1992","unstructured":"Davis, M. R., Manning, L. S., Whitaker, D., Garlepp, M. J. & Robinson, B. W. S. Establishment of a murine model of malignant mesothelioma. Int. J. Cancer 52, 881\u2013886 (1992).","journal-title":"Int. J. Cancer"},{"key":"42668_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/srep22850","volume":"6","author":"R Mezzapelle","year":"2016","unstructured":"Mezzapelle, R. et al. Human malignant mesothelioma is recapitulated in immunocompetent BALB\/c mice injected with murine AB cells. Sci. Rep. 6, 22850 (2016).","journal-title":"Sci. Rep."},{"key":"42668_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002071","volume":"9","author":"A Marcu","year":"2021","unstructured":"Marcu, A. et al. HLA ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy. J. Immunother. Cancer 9, e002071 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"42668_CR24","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1074\/mcp.M114.042812","volume":"14","author":"M Bassani-Sternberg","year":"2015","unstructured":"Bassani-Sternberg, M., Pletscher-Frankild, S., Jensen, L. J. & Mann, M. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Mol. Cell Proteom. 14, 658\u2013673 (2015).","journal-title":"Mol. Cell Proteom."},{"key":"42668_CR25","doi-asserted-by":"publisher","first-page":"e1002517","DOI":"10.1371\/journal.pcbi.1002517","volume":"8","author":"I Hoof","year":"2012","unstructured":"Hoof, I., van Baarle, D., Hildebrand, W. H. & Ke\u015fmir, C. Proteome sampling by the HLA class I antigen processing pathway. PLoS Comput. Biol. 8, e1002517 (2012).","journal-title":"PLoS Comput. Biol."},{"key":"42668_CR26","doi-asserted-by":"publisher","first-page":"100022","DOI":"10.1074\/mcp.R120.002309","volume":"20","author":"A Nelde","year":"2021","unstructured":"Nelde, A., Rammensee, H.-G. & Walz, J. S. The peptide vaccine of the future. Mol. Cell. Proteom. 20, 100022 (2021).","journal-title":"Mol. Cell. Proteom."},{"key":"42668_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003032","volume":"9","author":"J Harber","year":"2021","unstructured":"Harber, J., Kamata, T., Pritchard, C. & Fennell, D. Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy. J. Immunother. Cancer 9, e003032 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"42668_CR28","first-page":"1741","volume":"19","author":"S Inoue","year":"2020","unstructured":"Inoue, S. et al. Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer. Oncol. Lett. 19, 1741\u20131750 (2020).","journal-title":"Oncol. Lett."},{"key":"42668_CR29","doi-asserted-by":"publisher","first-page":"e1009894","DOI":"10.1371\/journal.ppat.1009894","volume":"18","author":"B Nicholas","year":"2022","unstructured":"Nicholas, B. et al. Immunopeptidomic analysis of influenza A virus infected human tissues identifies internal proteins as a rich source of HLA ligands. PLoS Pathog. 18, e1009894 (2022).","journal-title":"PLoS Pathog."},{"key":"42668_CR30","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jtho.2020.08.024","volume":"16","author":"ES Reardon","year":"2021","unstructured":"Reardon, E. S. et al. UHRF1 is a novel druggable epigenetic target in malignant pleural mesothelioma. J. Thorac. Oncol. 16, 89\u2013103 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"42668_CR31","doi-asserted-by":"crossref","unstructured":"Al\u00ec, G., Bruno, R. & Fontanini, G. The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review. J. Thorac. Dis. 10, S276\u2013S284 (2017).","DOI":"10.21037\/jtd.2017.10.125"},{"key":"42668_CR32","doi-asserted-by":"crossref","unstructured":"Bruno, R., Al\u00ec, G. & Fontanini, G. Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review. J. Thorac. Dis. 10, S342\u2013S352 (2017).","DOI":"10.21037\/jtd.2017.10.88"},{"key":"42668_CR33","first-page":"80","volume":"108","author":"JM Corson","year":"1982","unstructured":"Corson, J. M. & Pinkus, G. S. Mesothelioma: profile of keratin proteins and carcinoembryonic antigen: an immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas. Am. J. Pathol. 108, 80\u201388 (1982).","journal-title":"Am. J. Pathol."},{"key":"42668_CR34","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/BF00710235","volume":"406","author":"B Jasani","year":"1985","unstructured":"Jasani, B., Edwards, R. E., Thomas, N. D. & Gibbs, A. R. The use of vimentin antibodies in the diagnosis of malignant mesothelioma. Virchows Arch. A Pathol. Anat. Histopathol. 406, 441\u2013448 (1985).","journal-title":"Virchows Arch. A Pathol. Anat. Histopathol."},{"key":"42668_CR35","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.18632\/oncotarget.13174","volume":"8","author":"R Bruno","year":"2017","unstructured":"Bruno, R. et al. Malignant pleural mesothelioma and mesothelial hyperplasia: a new molecular tool for the differential diagnosis. Oncotarget 8, 2758\u20132770 (2017).","journal-title":"Oncotarget"},{"key":"42668_CR36","doi-asserted-by":"publisher","first-page":"4754","DOI":"10.1158\/0008-5472.CAN-18-4080","volume":"79","author":"YC Chang","year":"2019","unstructured":"Chang, Y. C. et al. Therapeutic targeting of aldolase A interactions inhibits lung cancer metastasis and prolongs survival. Cancer Res. 79, 4754\u20134766 (2019).","journal-title":"Cancer Res."},{"key":"42668_CR37","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.cels.2019.08.009","volume":"9","author":"LP Richman","year":"2019","unstructured":"Richman, L. P., Vonderheide, R. H. & Rech, A. J. Neoantigen dissimilarity to the self-proteome predicts immunogenicity and response to immune checkpoint blockade. Cell Syst. 9, 375\u2013382.e374 (2019).","journal-title":"Cell Syst."},{"key":"42668_CR38","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.cell.2020.09.015","volume":"183","author":"DK Wells","year":"2020","unstructured":"Wells, D. K. et al. Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction. Cell 183, 818\u2013834.e13 (2020).","journal-title":"Cell"},{"key":"42668_CR39","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217\u2013221 (2017).","journal-title":"Nature"},{"key":"42668_CR40","doi-asserted-by":"publisher","first-page":"15992","DOI":"10.1021\/acsnano.1c04371","volume":"15","author":"S Feola","year":"2021","unstructured":"Feola, S. et al. PeptiCHIP: a microfluidic platform for tumor antigen landscape identification. ACS Nano 15, 15992\u201316010 (2021).","journal-title":"ACS Nano"},{"key":"42668_CR41","doi-asserted-by":"publisher","first-page":"100110","DOI":"10.1016\/j.mcpro.2021.100110","volume":"20","author":"J Fritsche","year":"2021","unstructured":"Fritsche, J. et al. Pitfalls in HLA ligandomics\u2014how to catch a Li(e)gand. Mol. Cell. Proteom. 20, 100110 (2021).","journal-title":"Mol. Cell. Proteom."},{"key":"42668_CR42","doi-asserted-by":"publisher","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","volume":"48","author":"B Reynisson","year":"2020","unstructured":"Reynisson, B., Alvarez, B., Paul, S., Peters, B. & Nielsen, M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 48, W449\u2013W454 (2020).","journal-title":"Nucleic Acids Res."},{"key":"42668_CR43","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.omto.2021.02.006","volume":"20","author":"E Yl\u00f6sm\u00e4ki","year":"2021","unstructured":"Yl\u00f6sm\u00e4ki, E. et al. Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform. Mol. Ther. Oncolytics 20, 459\u2013469 (2021).","journal-title":"Mol. Ther. Oncolytics"},{"key":"42668_CR44","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.omtm.2021.01.014","volume":"20","author":"F Hamdan","year":"2021","unstructured":"Hamdan, F. et al. GAMER-Ad: a novel and rapid method for generating recombinant adenoviruses. Mol. Ther. Methods Clin. Dev. 20, 625\u2013634 (2021).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"42668_CR45","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1038\/s41388-018-0153-z","volume":"37","author":"H Rehrauer","year":"2018","unstructured":"Rehrauer, H. et al. How asbestos drives the tissue towards tumors: YAP activation, macrophage and mesothelial precursor recruitment, RNA editing, and somatic mutations. Oncogene 37, 2645\u20132659 (2018).","journal-title":"Oncogene"},{"key":"42668_CR46","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.3892\/ijo.2013.2125","volume":"43","author":"M Kawahara","year":"2013","unstructured":"Kawahara, M. & Takaku, H. Intradermal immunization with combined baculovirus and tumor cell lysate induces effective antitumor immunity in mice. Int. J. Oncol. 43, 2023\u20132030 (2013).","journal-title":"Int. J. Oncol."},{"key":"42668_CR47","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1182\/blood.2019002121","volume":"135","author":"O Dufva","year":"2020","unstructured":"Dufva, O. et al. Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. Blood 135, 597\u2013609 (2020).","journal-title":"Blood"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-42668-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-42668-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-42668-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T09:04:07Z","timestamp":1699002247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-42668-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,3]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["42668"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-42668-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2238403\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,3]]},"assertion":[{"value":"4 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"V.C. is co-founder and shareholder of Valo Therapeutics LTD. H.C. and L.K. are stakeholders of Valo Therapeutics LTD. All other named authors declare that they have no competing interests, financial or otherwise.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7056"}}